Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 03 - 22 save search
Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Published: 2021-03-22 (Crawled : 22:00) - globenewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M
|
Health Technology
|
| O: -2.35%
H: 0.49%
C: -2.0%
diabetes treatment
Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes
Published: 2021-03-22 (Crawled : 22:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -0.89%
H: 0.09%
C: -4.87%
diabetes treatment fda fda approval injection hypoglycemia approval pharma
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder
Published: 2021-03-22 (Crawled : 19:00) - globenewswire.com
TNXP | $0.1581 5.47% 5.19% 2M
|
Health Technology
|
| O: -3.36%
H: 0.69%
C: -4.17%
treatment fda results depression major depressive disorder
Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular AcneAccutane is Journey Medical’s sixth marketed dermatology product
Published: 2021-03-22 (Crawled : 14:00) - biospace.com/
FBIO | $1.79 1.7% 1.68% 240K
|
Health Technology
|
| O: 0.71%
H: 2.0%
C: -1.42%
treatment acne biotech license iot
Onychomycosis Treatment Manufacturers Find Opportunities in Novel Therapeutic Offerings: FMI Report
Published: 2021-03-22 (Crawled : 14:00) - biospace.com/
VTRS | $11.095 -0.22% -0.23% 6.1M
|
Health Technology
|
| O: 0.88%
H: 0.17%
C: -0.8%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -1.08%
H: 1.48%
C: 1.38%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: -0.79%
H: 1.1%
C: 0.91%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.64%
H: 1.2%
C: 0.39%
offering treatment
Psychedelics Becoming Valuable Alternatives to Conventional Mental Health Treatments
Published: 2021-03-22 (Crawled : 13:15) - prnewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.14%
H: 1.49%
C: 1.47%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -1.08%
H: 1.48%
C: 1.38%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.13%
H: 1.01%
C: 0.97%
CMPS | $8.53 -2.85% -2.93% 320K
|
Health Technology
|
| O: -1.94%
H: 3.92%
C: -0.13%
treatment health
Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne
Published: 2021-03-22 (Crawled : 13:15) - globenewswire.com
FBIO | $1.79 1.7% 1.68% 240K
|
Health Technology
|
| O: 0.71%
H: 2.0%
C: -1.42%
treatment acne biotech license iot
Patient-Centered Cancer Care: New Treatments and Defining Quality
Published: 2021-03-22 (Crawled : 13:00) - nanthealth.com
NH | $1.35 -46.64% -1.48% 0
|
Technology Services
|
| O: 0.0%
H: 2.02%
C: 0.58%
treatment cancer
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
Published: 2021-03-22 (Crawled : 13:00) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 19.65%
H: 6.28%
C: -5.8%
urea urine disease treatment commercialization collaboration license
RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland
Published: 2021-03-22 (Crawled : 12:00) - biospace.com/
RDHL | $0.3935 2.21% 2.16% 240K
|
Health Technology
|
| O: 2.13%
H: 1.82%
C: 0.0%
covid treatment biopharma switzerland opaganib covid-19
Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency
Published: 2021-03-22 (Crawled : 12:00) - biospace.com/
RCKT M | $23.7 -2.27% -2.32% 640K
|
Health Technology
|
| O: -0.64%
H: 7.12%
C: 1.8%
treatment phase 1 positive trial phase 3 phase 2
AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance
Published: 2021-03-22 (Crawled : 11:00) - investor.aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 5.67%
H: 0.0%
C: -5.91%
treatment renal commercialization cell carcinoma
Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis
Published: 2014-04-07 (Crawled : 07:00) - globenewswire.com
BAX | News | $39.52 -0.13% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
XBIO | $4.015 -4.09% 2.8K
|
Health Technology
| Email alert
Add to watchlist
treatment fibrosis phase 1 positive phase 3 phase 2 cystic fibrosis
Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava™ for the Treatment of Complicated Intra-abdominal Infections
Published: 2021-03-22 (Crawled : 03:00) - prnewswire.com
LJPC | $6.22 0.0%
|
Health Technology
|
| O: 0.19%
H: 1.99%
C: -3.6%
new drug treatment china drug injection infections
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.